Skip to main content

Table 3 Multivariable Regression Model of Steroid Exposure

From: Examining systemic steroid use in older inflammatory bowel disease patients using hurdle models: a cohort study

  Steroid use (yes/no)a Duration of steroid use among utilizersb
  OR CI Ratio of Durationsc CI
Age ( 5 year decrease) 1.25 (1.14, 1.39)f 0.97 (0.88, 1.06)
Female 1.30 (0.93, 1.80) 1.11 (0.85, 1.45)
Caucasian 1.46 (0.87, 2.46) 0.87 (0.54, 1.38)
Region     
 Midwest 1.00 Reference 1.00 Reference
 Northeast 0.92 (0.61, 1.37) 1.13 (0.81, 1.57)
 Southeast 0.91 (0.61, 1.35) 0.93 (0.67, 1.29)
 Southwest 0.80 (0.47, 1.38) 0.84 (0.54, 1.32)
 Rocky Mountain 0.44 (0.12, 1.55) 0.90 (0.29, 2.73)
 Pacific & HI, AK, PRg 0.70 (0.38, 1.30) 0.84 (0.51, 1.40)
Rural 1.54 (1.10, 2.13)d 0.93 (0.71, 1.20)
Medicaid eligible 0.80 (0.57, 1.13) 0.89 (0.66, 1.20)
antiTNFs 1.66 (0.52, 5.34) 0.63 (0.30, 1.29)
Nonbiologic immunomodulators 2.14 (0.82, 5.57) 0.76 (0.42, 1.36)
Aminosalicylates 1.78 (1.26, 2.51)e 1.01 (0.77, 1.33)
Locally administered steroids 3.77 (0.69, 20.6) 1.41 (0.46, 4.35)
Antidiarrheals 1.72 (1.12, 2.62)d 0.83 (0.59, 1.18)
Charlson index 0.96 (0.90, 1.01) 1.00 (0.95, 1.06)
Hospitalizations 0.97 (0.88, 1.07) 0.99 (0.90, 1.09)
Endoscopy (>1) 1.09 (0.76, 1.56) 0.83 (0.60, 1.15)
IBD-associated Surgery 0.75 (0.40, 1.39) 0.89 (0.48, 1.64)
  1. aDependent variable was incident steroid use during the follow-up period, Individuals with baseline steroid use were excluded from this model (n = 1216)
  2. bDependent variable was days of steroid use among steroid users (n = 260) during the follow-up period, Individuals with baseline steroid use were excluded from this model; count truncated at zero; cEffect measure is ratio of steroid therapy durations; All explanatory variables are measured within the first 12 months after study entry; d p < .05, e p < .01, f p < .001; gHI = Hawaii, AK = Alaska, PR = Puerto Rico